RESUMEN
Hepatic function was studied in 31 patients with coronary heart disease before and after treatment with nicardipine. Clinical and biochemical findings (enhanced gamma-glutamate transferase and high cholesterol, hepatobiliary syndrome) provide evidence for hepatic function disturbance associated with coronary heart disease. Nicardipine produced a good subjective response, the attenuation of hepatobiliary syndrome. Biochemical indices did not change.
Asunto(s)
Enfermedad Coronaria/tratamiento farmacológico , Hígado/efectos de los fármacos , Nicardipino/farmacología , Adulto , Enfermedad Coronaria/fisiopatología , Humanos , Hígado/fisiopatología , Pruebas de Función Hepática , Persona de Mediana Edad , Nicardipino/uso terapéuticoRESUMEN
When treated by verapamil, coronary patients responded differently. Hepatic effects can be either protective or toxic depending on the drug dosage and course duration. Verapamil hepatic protection manifests in day dosage 360 mg and the course duration 3 weeks. 600 mg verapamil is toxic irrespective of the course duration.